Abstract:Gastrointestinal cancers (GICs) are one of the most recurrent diseases in the world. Among all GICs, pancreatic cancer (PC) is one of the deadliest and continues to disrupt people's lives worldwide. The most frequent pancreatic cancer type is pancreatic ductal adenocarcinoma (PDAC), representing 90 to 95% of all pancreatic malignancies. PC is one of the cancers with the worst prognoses due to its non-specific symptoms that lead to a late diagnosis, but also due to the high resistance it develops to anticancer drugs. Gemcitabine is a standard treatment option for PDAC, however, resistance to this anticancer drug develops very fast. The microbiome was recently classified as a cancer hallmark and has emerged in several studies detailing how it promotes drug resistance. However, this area of study still has seen very little development, and more answers will help in developing personalized medicine. PC is one of the cancers with the highest mortality rates; therefore, it is crucial to explore how the microbiome may mold the response to reference drugs used in PDAC, such as gemcitabine. In this article, we provide a review of what has already been investigated regarding the impact that the microbiome has on the development of PDAC in terms of its effect on the gemcitabine pathway, which may influence the response to gemcitabine. Therapeutic advances in this type of GIC could bring innovative solutions and more effective therapeutic strategies for other types of GIC, such as colorectal cancer (CRC), due to its close relation with the microbiome.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the issue of microbiome - acquired resistance to gemcitabine treatment in pancreatic ductal adenocarcinoma (PDAC). Specifically, the paper explores how the microbiome affects the mechanism of action of gemcitabine and how this influence leads to resistance to gemcitabine in PDAC patients. By reviewing the existing literature, the author aims to reveal the role of the microbiome in the development of PDAC, especially its impact on the gemcitabine metabolic pathway, thereby providing a theoretical basis for the development of more effective personalized medical strategies.
### Background and Problem Description
Pancreatic cancer (PC) is one of the cancers with the highest mortality rate globally, among which pancreatic ductal adenocarcinoma (PDAC) is the most common, accounting for 90% - 95% of all pancreatic malignancies. PDAC is characterized by non - specific symptoms leading to delayed diagnosis and high resistance to chemotherapeutic drugs. Gemcitabine, as the standard treatment drug for PDAC, is effective, but patients quickly develop resistance to it. Research in recent years has shown that the microbiome may play an important role in promoting drug resistance, but research in this area is still in its infancy.
### Objectives of the Paper
This paper aims to synthesize existing research and explore how the microbiome affects the development of PDAC, especially its impact on the gemcitabine metabolic pathway. Specific objectives include:
1. **Review the role of the microbiome in the development of PDAC**: Analyze how the microbiome affects the progression of PDAC through different mechanisms.
2. **Explore the microbiome mechanisms of gemcitabine resistance**: Discuss in detail how the microbiome causes PDAC cells to develop resistance to gemcitabine by altering the gemcitabine metabolic pathway.
3. **Propose future research directions**: Based on existing research, propose potential research directions for further exploring the relationship between the microbiome and PDAC resistance, with the aim of developing more effective personalized treatment strategies.
### Main Contents
1. **Introduction**: Introduces the epidemiological characteristics of pancreatic cancer, the high mortality rate of PDAC, and its high resistance to chemotherapeutic drugs.
2. **Definition of the microbiome and its role in cancer**: Explains the concept of the microbiome and its role in the occurrence and development of cancer.
3. **Mechanism and resistance of gemcitabine**: Describes in detail the chemical structure, mechanism of action of gemcitabine and its application in PDAC treatment, with a focus on the mechanism of gemcitabine resistance.
4. **Relationship between the microbiome and gemcitabine resistance**: Reviews how the microbiome affects the metabolism of gemcitabine through different mechanisms (such as gene expression, signal pathways, etc.), causing PDAC cells to develop resistance to gemcitabine.
5. **Future research directions**: Proposes the focus of future research, including further exploring the relationship between the microbiome and PDAC resistance, and developing new treatment strategies.
### Conclusion
By synthesizing existing research, this paper emphasizes the important role of the microbiome in the development of PDAC, especially its impact on gemcitabine resistance. Future research needs to further explore the specific mechanisms of the microbiome in order to develop more effective personalized treatment strategies and improve the survival rate and quality of life of PDAC patients.